IMPAX Mourns The Death Of Dr. Charles Hsiao, Co-Founder And Chairman

September 15, 2008

HAYWARD, Calif. (September 15, 2008) – IMPAX Laboratories, Inc. sadly reports the recent death of Charles Hsiao, Ph.D., its long-time Chairman. Dr. Hsiao was a co-founder of the Company’s predecessor, Impax Pharmaceuticals, Inc., in 1995, and served as the Company’s Co-Chief Executive Officer from 1999 to 2003.  Long regarded as a leader in the generic pharmaceutical industry, in 1986 Dr. Hsiao was one of three co-founders of IVAX Corporation, which, by 1994, when he left the Vice-Chairman position at IVAX, had become the world’s largest generic pharmaceutical company at the time. 

While Dr. Hsiao co-led IMPAX’s research and development activities for a number of years, on January 1, 2004 he transitioned from the Company’s day-to-day product development activities and took charge of long-term exploratory research activities with a newly established laboratory located at Pleasanton, California.  His creative approaches and intellectual curiosities have been instilled in a team of talented scientists at Impax who continue to excel in formulation and drug delivery technology.

Larry Hsu, Ph.D, President and Chief Executive Officer, who co-founded IMPAX with Dr. Hsiao, said: “Charlie’s passing will be a great loss. His leadership, entrepreneurial spirit, scientific expertise and significant accomplishments were a substantial factor in the formation and growth of the Company.  As we grieve this tragic loss, Charlie’s passion for the continued success and growth of the Company will live on.”  

About IMPAX Laboratories, Inc.

IMPAX Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. IMPAX markets its generic products through its Global Pharmaceuticals division and markets its branded products through the IMPAX Pharmaceuticals division. Additionally, where strategically appropriate, IMPAX has developed marketing partnerships to fully leverage its technology platform. IMPAX Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward and Philadelphia facilities. For more information, please visit the Company's Web site at: www.impaxlabs.com.

Company Contacts

IMPAX Laboratories, Inc.

Larry Hsu, Ph.D. President & CEO
(510) 476-2000, Ext. 1111 ;
Arthur Koch, CFO
(215) 933-0351
Mark Donohue, Sr. Director IR
(215) 933-3526
www.impaxlabs.com

Investor Relations Contacts:

Lippert/Heilshorn & Associates, Inc.

Kim Sutton Golodetz
(kgolodetz@lhai.com)
(212) 838-3777
Bruce Voss (bvoss@lhai.com)
(310) 691-7100
www.lhai.com